Detalhe da pesquisa
1.
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
Ann Rheum Dis
; 83(4): 421-428, 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38071508
2.
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care.
J Rheumatol
; 51(4): 378-389, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38224992
3.
After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries.
Ann Rheum Dis
; 82(2): 175-181, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36100351
4.
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
Ann Rheum Dis
; 81(10): 1358-1366, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35705376
5.
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis.
Rheumatology (Oxford)
; 61(12): 4741-4751, 2022 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35323903
6.
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response.
Rheumatology (Oxford)
; 61(9): 3799-3807, 2022 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34940840
7.
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
Ann Rheum Dis
; 80(11): 1410-1418, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34083206
8.
Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis.
Rheumatology (Oxford)
; 59(9): 2455-2461, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31960053
9.
Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution.
Rheumatology (Oxford)
; 58(12): 2221-2229, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31209481
10.
The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs.
Pharmacol Res
; 148: 104410, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31461667
11.
Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
Pain Pract
; 16(5): 600-19, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26554630
12.
Early identification of golimumab-treated patients with higher likelihood of long-term retention.
Front Immunol
; 15: 1359571, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38680482
13.
Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry.
Arthritis Res Ther
; 26(1): 57, 2024 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38395899
14.
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies.
Joint Bone Spine
; 91(2): 105671, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38042363
15.
Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases.
Adv Rheumatol
; 63(1): 25, 2023 06 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37287051
16.
Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.
Musculoskeletal Care
; 21(1): 189-197, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35996810
17.
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment.
J Rheumatol
; 50(8): 1009-1019, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36455943
18.
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries.
Arthritis Care Res (Hoboken)
; 74(7): 1205-1218, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33460531
19.
Adherence to Treatment in Patients with Rheumatoid Arthritis from Spain.
Patient Prefer Adherence
; 15: 111-117, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33531797
20.
Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry.
Clin Rheumatol
; 40(10): 3979-3988, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33907904